Therapies
Fc-engineered lgG1 & IgG3 variants with improved FcRn binding through REW amino acid substitutions
Technology No. DOFI 16003
HLA-II targeting vaccines
Technology No. DOFI 15340
Lumiblast™
Technology No. DOFI 16017
MUC16 CAR-T therapy to treat ovarian cancer
Technology No. DOFI 21046
Novel photosensitizer for PCI
Technology No. DOFI 24078
STEAP1 CAR for metastatic prostate cancer
Technology No. DOFI 18126
Switch receptor for use in adoptive cell therapy
Technology No. DOFI 22092
Tandem antibody technology
Technology No. DOFI 20116
Tankyrase inhibition for therapy of lung fibrosis
Technology No. DOFI 15327